PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Reveals whether the business's core operations generate sufficient cash to cover expenses, fund growth, and return capital to shareholders. Sustainable free cash flow is often a key indicator of long-term value creation.
0.02
OCF/share below $1 – Weak cash generation. Howard Marks would be cautious, demanding deeper diligence of liquidity.
0.02
FCF/share below $0.5 – Very weak. Howard Marks would consider liquidity risks and heavy capital demands.
No Data
No Data available this quarter, please select a different quarter.
0.44
Below 1.0 – Earnings may outstrip actual OCF. Howard Marks would caution about potential accrual or earnings quality issues.
No Data
No Data available this quarter, please select a different quarter.